anti-dectin-2 agonist monoclonal antibody bdc-3042
Generic: Anti-dectin-2 Agonist Monoclonal Antibody BDC-3042
anti-dectin-2 agonist monoclonal antibody bdc-3042: 1 clinical trial tracked.
anti-dectin-2 agonist monoclonal antibody bdc-3042 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-dectin-2 agonist monoclonal antibody bdc-3042, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trial Registry Records (1)
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Primary endpoint: Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to CTCAE v5.0
Interventionalopen17 enrolledStarted 2023-10Completion 2025-086 sites · United StatesBolt Biotherapeutics, Inc.